摘要
目的探讨生长抑素和质子泵抑制剂联合应用预防内镜逆行胰胆管造影(endoscopic retrograde cholangiopancre-atography,ERCP)术后胰腺炎的作用。方法201例胆胰疾病患者分为用药组97例及对照组104例。用药组ERCP术后用奥曲肽0.1mg皮下注射q8h×24h,泮托拉唑40mg滴注q12h×48h,对照组用生理盐水500ml滴注。ERCP术前,术后6h及24h查血清淀粉酶并观察有无急性胰腺炎的临床表现。结果ERCP术后用药组和对照组急性胰腺炎的发生率分别为2.06%、8.65%,P<0.01;术后6h及24h高淀粉酶血症的发生率分别为28.87%、48.12%(P<0.05)和11.34%、27.88%(P<0.05)。结论生长抑素和质子泵抑制剂联合应用可减少ERCP术后胰腺炎的发生率。
Objective To investigate the preventive role in acute pancreatitis induced by endoscopic retrograte cholangiopancreaticography （ERCP） with both somatostatin and proton pump inhibitor. Methods Two hundred one patients were divided into the somatostatin and proton pump inhibitor （PPI） treated and control groups. The treated group was injected subcutaneously both with Sandostatin 0. 1mg q8h×24h and received interavenously injection of Pantanrazole 40mg q12h× 48h, the control group interavenously injection of normal saline. Blood was drawn in each group the day before, 6h and 24h following ERCP for amylase measurement. Clinical manifestations of acute pancreatitis were also observed. Results Acute pancreatitis was clinically established in 2.06% of the treated group, significantly lower than that of control group（8.65% ,P〈0.01）. At 6h and 24h of post-ERCP, hyperamylasemia occurred in 28.870% and 11.34 % patients in the treated group, significantly lower than control group（48.12 % and 27.88% P〈0.05）. Conclusion The use of both somatostatin and proton pump inhibitor can prevent acute pancreatitis induced by ERCP.
出处
《重庆医学》
CAS
CSCD
2005年第11期1662-1663,共2页
Chongqing medicine
关键词
生长抑素
质子泵抑制剂
内镜逆行胰胆管造影术后胰腺炎
预防
somatostatin
proton pump inhibitor
prevention
acute pancreatitis induced by endoscopic retrograte cholangiopancreaticography
prevention
